Quantcast

Latest Everolimus Stories

2014-09-15 12:26:57

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time ABBOTT PARK, Ill., Sept. 15, 2014 /PRNewswire/ -- Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the...

2014-09-14 12:20:52

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time WASHINGTON, Sept. 14, 2014 /PRNewswire/ -- Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES. The trial,...

2014-07-21 16:26:15

Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients MARLBOROUGH, Mass., July 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease (CAD). Bare-metal stents continue to play an important role in the treatment of CAD and represent a...

2014-07-15 08:28:52

Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, July 15, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the medical device industry, will be based in the Company's Boston headquarters. Dr. Barry will focus on three critical...

2014-07-02 12:13:46

The JAMA Network Journals Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve...

2014-05-21 08:29:14

EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile NATICK, Mass., May 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium (PtCr) Coronary Stent System to the PROMUS Element(TM) Stent System. The data were presented today at EuroPCR 2014 by...

2014-05-01 00:21:42

NATICK, Mass., May 1, 2014 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval. "It is my great pleasure to be able to provide the Promus PREMIER(TM) Stent System to physicians and patients in Japan,"...

2014-04-10 08:30:25

- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb(TM) Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market....

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-04-02 00:23:28

These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease NATICK, Mass., April 1, 2014 /PRNewswire/ -- Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related